Novel artificial intelligence platform for drug development and personalized medicine
Our current applications
Our Services
HEALTH CARE ONCOLOGY WORKFLOW
HEALTH CARE ONCOLOGY WORKFLOW
- FDA Approved Drugs
- Medical indications
- Pharmacology toxicities
- Drugs interactions
- Ongoing clinical studies
- European and American guidelines
- Molecular Biomarkers for personalized medicine
- Real World Data
- Best workflow to reduce medical effort
PRECISION MEDICINE SOLUTIONS
PRECISION MEDICINE SOLUTIONS
- Genomic Molecular Alterations
- Evaluation of oncogenic molecular panels
- Druggable vulnerabilities
- Targered agents
- Therapeutic opportunities
- Drug combinations
- Ongoing clinical studies
- Identification of best treatment based on propietary algorithms
BIOMARKER AND DRUG DEVELOPER
BIOMARKER AND DRUG DEVELOPER
- Genomic molecular alterations
- Potential target inhibition
- Druggable vulnerabilities
- Current clinical development
- Competitive landscape
- Target population and indication
- Evaluation of attrition rate
- Pharma intelligent
- Identification of best clinical development
What we do
This platform uses data from different sources including molecular alterations, scientific results, clinical trials, combinations of compounds, described efficacy, competitive landscape, in addition to side effects or potential interactions, to provide the user with all relevant data in a customized manner, without the necessity to obtain this information through complex consulting dossiers.
In addition, we are developing algorithms that can help to predict the success of a new pharmacological compound through the identification of unmet necessities, empty areas, potential side effects or combinations that would not reach the clinical setting, as well as crowded sectors or areas for business development.
Request an online test
We would be happy to show you our platform.
Named as one of the Top Ten Drug Discovery
CancerAppy Contributes to Innovative Scientific Paper on ADCs in Clinical Use
CancerAppy pioneers in ADC research, contributing to a transformative scientific paper. Our team's dedication unveils insights on payload properties, shaping the future of ADC therapies. A crucial leap in cancer treatment. We are proud to announce our significant...
CancerAppy at ESMO Congress: Pioneering Research Unveiled!
CancerAppy's groundbreaking study at ESMO Congress (Oct '23) reveals profound insights into Treg impact on tumor immune responses. Unearthing common transcripts and potential predictors, our AI-driven research shapes the future of cancer treatment.CancerAppy has...